110 related articles for article (PubMed ID: 12113107)
1. Therapy options in cutaneous T-cell lymphoma.
Apisarnthanarax N; Duvic M
Expert Rev Anticancer Ther; 2001 Oct; 1(3):403-20. PubMed ID: 12113107
[TBL] [Abstract][Full Text] [Related]
2. Current management strategies for cutaneous T-cell lymphoma.
Knobler E
Clin Dermatol; 2004; 22(3):197-208. PubMed ID: 15262305
[TBL] [Abstract][Full Text] [Related]
3. Update on treatment of cutaneous T-cell lymphoma.
Gardner JM; Evans KG; Musiek A; Rook AH; Kim EJ
Curr Opin Oncol; 2009 Mar; 21(2):131-7. PubMed ID: 19532014
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
Whittaker SJ; Foss FM
Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
[TBL] [Abstract][Full Text] [Related]
5. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what?
Dummer R; Assaf C; Bagot M; Gniadecki R; Hauschild A; Knobler R; Ranki A; Stadler R; Whittaker S
Eur J Cancer; 2007 Nov; 43(16):2321-9. PubMed ID: 17707638
[TBL] [Abstract][Full Text] [Related]
6. The optimal use of bexarotene in cutaneous T-cell lymphoma.
Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
[TBL] [Abstract][Full Text] [Related]
7. Staging and management of cutaneous T-cell lymphoma.
Scarisbrick JJ
Clin Exp Dermatol; 2006 Mar; 31(2):181-6. PubMed ID: 16487086
[TBL] [Abstract][Full Text] [Related]
8. Treatment of cutaneous T cell lymphoma: current status and future directions.
Apisarnthanarax N; Talpur R; Duvic M
Am J Clin Dermatol; 2002; 3(3):193-215. PubMed ID: 11978140
[TBL] [Abstract][Full Text] [Related]
9. Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL).
Dummer R
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S33-6. PubMed ID: 16516674
[TBL] [Abstract][Full Text] [Related]
10. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
Martin AG
J Drugs Dermatol; 2003 Apr; 2(2):155-67. PubMed ID: 12852367
[TBL] [Abstract][Full Text] [Related]
11. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
[TBL] [Abstract][Full Text] [Related]
12. Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma.
Miller JD; Kirkland EB; Domingo DS; Scull H; Jekutis B; Dallas M; Cooper KD; Baron ED
Photodermatol Photoimmunol Photomed; 2007 Oct; 23(5):163-71. PubMed ID: 17803594
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment modalities in cutaneous T-cell lymphoma (CTCL).
Guitart J
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S17-20. PubMed ID: 16516671
[TBL] [Abstract][Full Text] [Related]
14. Management of refractory early-stage cutaneous T-cell lymphoma.
Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic approaches in cutaneous lymphoma.
Jörg B; Kerl H; Thiers BH; Bröcker EB; Burg G
Dermatol Clin; 1994 Apr; 12(2):433-41. PubMed ID: 8045054
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous T-cell lymphoma in skin of color.
Hinds GA; Heald P
J Am Acad Dermatol; 2009 Mar; 60(3):359-75; quiz 376-8. PubMed ID: 19231637
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
18. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.
Ferenczi K; Yawalkar N; Jones D; Kupper TS
Arch Dermatol; 2003 Jul; 139(7):909-13. PubMed ID: 12873887
[TBL] [Abstract][Full Text] [Related]
19. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
Geskin L
Skin Therapy Lett; 2007 Jun; 12(5):1-4. PubMed ID: 17609808
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
Dummer R; Foss F; Dreno B; Bagot M
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
